FDA Warns Lunesta and Generics Can Cause Next-Day Impairment: AttorneyOne Monitor and Keep Consumers Informed

On May 15, the FDA warned that Eszopiclone Containing Sleep Aids (including Lunesta and generics) can cause next-day impairment of driving and other activities that require alertness. In light of this news, AttorneyOne, a recognized authority on law, updated the website providing detailed information to consumers.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friendRepost This
Lunesta: Drug Safety Communication

Lunesta: Drug Safety Communication

our focus should squarely fall on investigating these safety alerts and getting the word out

San Diego, CA (PRWEB) May 20, 2014

AttorneyOne.com, a recognized authority on law, update the website daily regarding all the latest information from the FDA on safety alerts for Lunesta.

As the FDA communicated on May 15, a study of Lunesta found that the previously recommended dose of 3 mg can cause next-day impairment to coordination, memory, and driving skills. The Agency recommends lowering the starting dose of Lunesta to 1 mg at bedtime.

The Lunesta prescribing information and the patient Medication Guide together with the drug labels of generic eszopiclone products will include the new recommendations.

Taking into consideration the latest developments, AttorneyOne.com monitor daily and update the website providing accurate information on all relevant FDA safety alerts. Sean Burke, director of Media Relations at AttorneyOne.com, adds “we are determined to keep an eye on FDA announcements concerning Lunesta and inform the public. For that reason", he continues, "our focus should squarely fall on investigating these safety alerts and getting the word out.”

As the FDA advises “Health care professionals should follow the new dosing recommendations when starting patients on Lunesta. Patients should continue taking their prescribed dose of Lunesta and contact their health care professionals to ask about the most appropriate dose for them.” And the Agency adds “FDA is continuing to evaluate the risk of impaired mental alertness with the entire class of sleep aid drugs, including over-the-counter drugs available without a prescription, and will update the public as new information becomes available.”

AttorneyOne.com has further information on Lunesta at the website including latest major drug and medical products law news.

Headquartered in San Diego, CA Attorney One was founded in 2004 and is not a law firm. They offer a nationwide legal service which helps consumers find the best representation for their legal needs. You can learn more about Attorney One at our website http://www.attorneyone.com. You can also find us on Facebook at http://www.facebook.com/AttorneyOne. Checkout earlier news from us at http://www.prweb.com/releases/2014/05/prweb11863874.htm